10-Q quarterly report · filed Nov 5, 2026

ANI PHARMACEUTICALS INC (ANIP) Q3 2026 10-Q Quarterly Report

Short answer

ANI PHARMACEUTICALS INC (ANIP) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $291M (up 27.6% year over year) with net income of $35M.

Q3 2026 key financials · XBRL

Revenue
$291M
+27.6% YoY · +9.3% QoQ
Net income
$35M
+32.1% YoY · +42.2% QoQ
Operating margin
18.0%
EPS (diluted)
$1.54
+40.0% YoY · +48.1% QoQ

Source: XBRL data from the ANI PHARMACEUTICALS INC (ANIP) Q3 2026 10-Q on SEC EDGAR. USD.

ANI PHARMACEUTICALS INC Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $290.8M, up 27.6% YoY from $227.8M
  • Operating margin 18.0% vs 16.1%; net margin 12.0% vs 11.8%
  • Best performer: Cortrophin Gel revenue $138.7M, up 36.1%; worst: Brands revenue $10.0M, down 6.5%
  • Cash $420.8M vs $285.6M at December 31, 2025; nine-month operating cash flow $198.8M vs $154.9M
  • Q3 share repurchases $7.5M; management expects resources sufficient for obligations over next 12 months, with financing needs possible if assumptions change

Risk Factors

  • New acquisition risk: Egetis offer requires 90% tender acceptance and regulatory clearances, including HSR and foreign-investment approvals
  • Most material update: Offer failure could leave significant transaction costs and depress ANI’s share price
  • Regulatory risk: Swedish takeover conditions include government approvals and potential restrictions or divestitures
  • Financial risk: $676.0 million 364-day bridge facility may require substantial cash servicing and refinancing
  • Currency risk: SEK 5.6 billion purchase consideration remains unhedged against Swedish krona appreciation

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ANI PHARMACEUTICALS INC quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.